Factor VIII (F8) Mouse Monoclonal Antibody [Clone ID: MH104]

Specifications

Product Data
Clone Name	MH104
Applications	ELISA, IHC, WB
Recommend Dilution	ELISA: 1:5,000; detection and quantitation of human factor VIII. Immunoblotting. Immunohistochemistry on frozen sections.
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Immunogen	Human factor VIII antigen
Specificity	MH104 is specific for human factor VIIIc, a 300 kD protein present in plasma in a complex with von Willebrandt factor. Involved in the clotting cascade (activated by thrombin) by forming a complex with factor IXa, calcium, and phospholipids. Elevated levels of factor VIII have been associated with acute and chronic liver diseases, vascular disorders, diabetes and with acutephase reactions.
Formulation	PBS, pH 7.4 containing 0.09 % NaN3, 0.5% BSA State: Purified State: Lyophilized purified IgG
Reconstitution Method	Restore in 1 ml dist. water
Purification	Protein A affinity chromatography
Conjugation	Unconjugated
Storage Condition	Prior to reconstitution store at 2-8°C. Following reconstitution store the antibody at -20°C. Avoid repeated freezing and thawing.
Gene Name	coagulation factor VIII
Database Link	Entrez Gene 2157 Human UniProt ID P00451
Background	Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is nonfunctional; i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.
Synonyms	Procoagulant component, Antihemophilic factor, F8C, AHF
Reference Data

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.